logo
Parkinson's: Cough medicine may help slow down cognitive decline

Parkinson's: Cough medicine may help slow down cognitive decline

Parkinson's disease dementia develops in people who have a Parkinson's disease diagnosis. Experts are interested in finding the best ways to address and prevent Parkinson's disease dementia. A randomized clinical trial found that the drug Ambroxol may help stabilize the neuropsychiatric symptoms of Parkinson's disease dementia, and confirmed the safety of the drug's use among participants. Dementia is a common problem that remains a critical focus of clinical research. One subtype of dementia is Parkinson's disease dementia, which has to do with the mental changes that occur in some people who already have Parkinson's disease. A study published in JAMA Neurology compared the outcome of the expectorant Ambroxol with a placebo among participants with Parkinson's disease dementia.While primary and secondary outcomes were similar, participants on the placebo experienced worsening neuropsychiatric symptoms compared to symptoms remaining the same in the intervention group.The results also showed a possible improvement in cognitive symptoms for people with variants of a particular gene. Ambroxol for brain health: Potential and limitationsThe authors of the current study note the need for disease-modifying interventions for Parkinson's disease dementia. They note that focusing on a particular enzyme, beta-glucocerebrosidase, has potential, with an increase in this enzyme possibly making things better. They also note that the medication Ambroxol affects this enzyme. This study involved examining the safety of Ambroxol, how well participants tolerated the medication, and how it affected cognitive symptoms. There were 55 participants in total. All participants were over 50 years old and had confirmed Parkinson's disease for 1 year or more before developing dementia. All participants also had a study partner, someone who was in contact with them 'at least 4 days per week.'Participants took either Ambroxol or the placebo for 1 year. Researchers had trouble with recruitment for a low-dose Ambroxol group, so this group was not included in the statistical analyses of primary and secondary outcomes. Overall, there were 22 participants in the high-dose Ambroxol group and 24 participants in the placebo group. As a primary outcome, researchers evaluated participants' conditions using two evaluations: the Clinician's Global Impression of Change and the Alzheimer Disease Assessment Scale-cognitive subscale version 13. They also used other evaluation tools for secondary outcomes, including the Parkinson's Disease Cognitive Rating Scale, the Clinical Dementia Rating Scale, and the neuropsychiatric inventory. Researchers were able to look at cerebral spinal fluid and plasma biomarkers in some participants as well. Throughout the study, some participants withdrew due to adverse events. Eight participants in the Ambroxol group withdrew, and three in the placebo group withdrew.Participants in the Ambroxol group saw more gastrointestinal adverse events. The placebo group experienced more psychiatric adverse events and falls than the intervention group. In the statistical analyses, the primary and secondary outcomes between the two groups were about the same. Thus, Ambroxol did not appear to have a significant impact on cognition. However, researchers did observe that the neuropsychiatric inventory stayed the same for the Ambroxol group, but the placebo group got worse in this area, indicating the placebo group experienced worsening behavioral functioning. People at high risk of Parkinson's dementia may benefit moreThe authors of the study note that GBA1 gene variants can increase the risk for cognitive decline in people who have Parkinson's disease, and that 'homozygous disease-causing variants in GBA1' can increase the risk for Parkinson's disease. In participants with GBA1 gene variants, those taking the high-dose Ambroxol had decreases in neuropsychiatric inventory scores, three to a level of 'clinically meaningful improvement,' and three also had clinically important improved cognitive scores.Researchers also observed increased beta-glucocerebrosidase levels among Ambroxol participants at the 26-week mark. Study author Stephen H. Pasternak, MD, PhD, FRCPC, a specialist in neurology, explained the following about the study to Medical News Today: 'Our goal was to test the safety and tolerability of Ambroxol and to assess its effect on cognition. We randomized 55 patients to Ambroxol 1,050 mg/day [milligrams per day] or placebo for 1 year. Ambroxol was well tolerated; we only saw stomach upset as a side effect, and it was mostly mild. Patients on Ambroxol had fewer psychiatric symptoms. Patients on placebo had a worsening of plasma GFAP, a marker of neurodegeneration. A subgroup of patients (with GBA1 mutations) appeared to have improved cognition.'How might a cough medication help maintain cognitive function?Pasternak told MNT that: 'We hope that Ambroxol, or drugs like Ambroxol, will be able to prevent the onset of Parkinson's disease and dementia if it is given early enough.' While more research is needed, this study sets up the possibility of using Ambroxol in the future to help people with Parkinson's disease dementia. Daniel Truong, MD, a neurologist, medical director of the Truong Neuroscience Institute at MemorialCare Orange Coast Medical Center in Fountain Valley, CA, and editor-in-chief of the Journal of Clinical Parkinsonism and Related Disorders, who was not involved in this research, explained that with future research this could lead to 'a new class of disease-modifying therapy for [Parkinson's disease dementia].Hypothesising on the potential mechanisms of action, Truong explained that:'Ambroxol, by enhancing lysosomal function via GCase [beta-glucocerebrosidase], may slow underlying neurodegeneration, especially in GBA1-related PDD [Parkinson's disease dementia] — marking a shift toward targeted disease modification rather than purely symptomatic treatment.' He also noted that this could lead to 'repurposing an established drug' as 'Ambroxol is already widely used as a mucolytic agent with a known safety profile.''This reduces development time, regulatory barriers, and cost, making it more feasible for rapid clinical adoption — especially in resource-limited settings,' Truong added.However, while it is commonly used in medical settings in many European countries, the expectorant drug is currently not approved in the United States by the Food and Drug Administration (FDA).Still, should the current study findings be confirmed by further research, Pasternak hopes experts may see the drug in a new light.'Current therapies for Parkinson's disease and dementia address symptoms but do not stop the underlying disease. These [new] findings suggest Ambroxol may protect brain function, especially in those genetically at risk. It offers a promising new treatment avenue where few currently exist,' he noted in a press release.More research needed to confirm findingsThe study does have a few limitations. It was a fairly small study with mostly white male participants that only went on for one year. It is possible that 1 year was not long enough to evaluate changes in cognitive symptoms since the placebo group did not see declines in cognitive symptoms.Researchers also note that the study was limited since it was a phase 2 trial out of a single center. They also acknowledge difficulties in recruitment and retention, and note that participants had 'limited ability to tolerate the long cognitive assessments.' The researchers did not get to conduct statistical analyses to look at differences between high and low doses of Ambroxol. They also note that the low-dose group appeared to have worse cognition. They suggest that future studies should possibly stratify participants by cognitive severity. They also acknowledge that it is possible that the Alzheimer Disease Assessment Scale-cognitive subscale version 13 might not have been sensitive enough to detect changes in 1 year in participants who had mild Parkinson's disease dementia. All participants in this study only had mild to moderate dementia. Finally, only eight participants total had GBA1 gene variants, so more research is needed to see if people in this group could experience distinct benefits from Ambroxol. Only three participants with GBA1 gene variants had the minimal clinically important difference in cognitive scores, and researchers acknowledge that 'this sample is too small to support any conclusion.' Pasternak and his colleagues are planning to conduct a follow-up clinical trial later in 2025. The current research received funding from the Garfield Weston Foundation, a grant-giving nongovernmental organisation in the United Kingdom.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bitter blow for diet soft drink lovers as groundbreaking Aussie research reveals what it's really doing to your body
Bitter blow for diet soft drink lovers as groundbreaking Aussie research reveals what it's really doing to your body

Daily Mail​

time10 minutes ago

  • Daily Mail​

Bitter blow for diet soft drink lovers as groundbreaking Aussie research reveals what it's really doing to your body

Just one can of artificially-sweetened soft drink per day can drastically increase the chance of developing type II diabetes, a new scientific study claims. The research out of Melbourne's Monash University suggests artificial sweeteners could raise the risk of developing the disease by nearly 40 per cent. Drinks using these ingredients - which do not raise blood sugar as much as regular sucrose despite being sweeter - are often marketed as a healthier alternative to the traditional sugar-filled beverages they replace. Health agencies have been debating ways to decrease sugar intake - including a tax on the product to curb its demand - after it was linked with the obesity epidemic in the West. RMIT University teamed up with Monash University to produce the new study, led by Distinguished Professor Barbora de Courten, that followed more than 36,000 people over nearly 14 years. Professor de Courten said one of the most shocking discoveries was that even people who are a healthy weight have a significant risk of developing diabetes via sweeteners. In recent years there has been a rise of natural alterative sweeteners such as stevia and monk fruit instead of older artificial products like like the out-of-fashion aspartame and saccharin. The study did not specify between the different types of artificial sweeteners. The results of the study were adjusted based on the weight measurement of participants, which only impacted the results of the artificial sugar test group. This implied that these drinks increased the risk of illness regardless of how heavy the person was who drank them. Professor de Courten advised health professionals to be cautious about what they recommend to patients. ​​​​'Artificial sweeteners are often recommended to people at risk of diabetes as a healthier alternative, but our results suggest they may pose their own health risks,' she said.​​​ Co-author, Monash PhD student Robel Hussen Kabthymer warned, however, that the findings did not mean normal sugar drinks are suddenly any healthier. The study found regular sugary drinks increased the risk of type II diabetes by about 23 per cent and 'surprisingly' artificial sweeteners increased it by about 38 per cent. Researchers discovered adults who drank seven or more of sugar soft drinks per week had a 23 per cent higher chance of developing the disease. Those who drank the same amount of artificial sugar drinks had a 38 per cent chance of the same happening to them. Professor de Courten suggested other factors like artificial sweeteners' impact on gut bacteria might be to blame. More than 36,000 people took part in the research which was assisted by volunteers from Cancer Council Victoria. The research took place over 14 years and its final result has been published in the Diabetes & Metabolism journal. These findings follow experts having implored the Albanese government to tax sugar in order to make the country healthier. MP Michael Freelander has previously been a vocal advocate for the proposed tax which he said should come alongside a broader public education effort about the harms of excess sugar. The Australian Medical Association (AMA) has specifically proposed a new tax at a rate of 50c per 100g of added sugar for each of these drinks to be paid by beverage manufacturers. The association believes this will curb Australia's dualling diabetes and obesity epidemics. If it were to be introduced it would mean a 375mL of normal Coke with 39.8g of sugar would be hit with a tax of 19.9c. The Albanese government has rejected the idea for a new tax and has instead said it will work with manufacturers to bring sugar contents down.

A single injection for newborns could protect them against HIV for years, study suggests
A single injection for newborns could protect them against HIV for years, study suggests

The Independent

time40 minutes ago

  • The Independent

A single injection for newborns could protect them against HIV for years, study suggests

A single injection at birth could shield children from HIV for years, a study has suggested. The study is one of the first to show that the first weeks of life offer a critical window where the immune system is naturally more tolerant, meaning it is the optimal time to deliver gene therapies that would otherwise be rejected at older ages. Researchers hope the gene therapy jab could be used in the future to fight against paediatric infections in high-risk areas. 'Nearly 300 children are infected with HIV each day,' said first author Amir Ardeshir, associate professor of microbiology and immunology at the Tulane National Primate Research Center in the US. 'This approach could help protect newborns in high-risk areas during the most vulnerable period of their lives.' The study, published in the journal Nature, created a gene therapy that programs cells to produce HIV-fighting antibodies. An animal study that tested the injection on non-human primates found it protected them from infection for at least three years without the need for a booster shot. But this was only if the injection was administered in the first month of life. In comparison, those that received the gene therapy between eight and 12 weeks after birth did not tolerate the treatment, study authors explain. 'This is a one-and-done treatment that fits the critical time when these mothers with HIV in resource-limited areas are most likely to see a doctor,' Dr Ardeshir said. 'As long as the treatment is delivered close to birth, the baby's immune system will accept it and believe it's part of itself.' Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization (WHO). But if they do not receive medication, the rate of transmission of HIV from the mother to her child either during pregnancy, labour, delivery or breastfeeding ranges between 15 per cent and 45 per cent, according to WHO data. Although antiviral treatments can suppress the virus and limit transmission, adherence to treatment and doctor visits decline after childbirth, particularly in areas with limited access to healthcare, the study authors noted. This gene therapy uses a harmless virus that can deliver genetic code to cells, but is different to a vaccine. This virus was injected into muscle cells and delivered instructions to produce antibodies that are capable of neutralising multiple strains of HIV. Researchers explained that previous studies have found repeated infusions of the injection are needed for it to work. But by injecting it into muscle cells, researchers say they become 'micro-factories that just keep producing these antibodies'. Newborns showed greater tolerance to the jab, which prevented infection during breastfeeding. However, older infants and juveniles were more likely to have produced anti-drug antibodies that shut down the treatment. In addition, exposing a foetus to the antibodies from the gene therapy before birth helps older infants accept the therapy. However, because it has only been tested on animals, researchers still do not know if it will work on human children. If successful, this treatment could dramatically reduce mother-to-child HIV transmission rates in high-risk regions such as sub-Saharan Africa, where 90 per cent of paediatric HIV cases can be found. 'Nothing like this was possible to achieve even 10 years ago,' Dr Ardeshir said. 'This was a huge result, and now we have all the ingredients to take on HIV.'

Cancer-causing chemical hiding in incredibly common coffee machines should be 'avoided at all costs'
Cancer-causing chemical hiding in incredibly common coffee machines should be 'avoided at all costs'

Daily Mail​

time40 minutes ago

  • Daily Mail​

Cancer-causing chemical hiding in incredibly common coffee machines should be 'avoided at all costs'

Your at-home coffee machine may be pushing you toward a cancer-related death, doctors say. Experts are warning against using coffee makers made of black plastic over fears the material contains high levels of cancer-causing chemicals and flame retardants. Kitchen utensils, electronics and coffee machines are made of recycled plastic that is melted together from different colored items, which gives it a messy and unappealing color. As a result, manufacturers commonly add a dye known as carbon black to the recycled products to turn them into a consistent black color to look sleeker and uniform. Studies have shown that carbon black contains numerous compounds, such as polycyclic aromatic hydrocarbons (PAHs), that are carcinogenic. As a result, the International Agency for Research on Cancer classified carbon black as a carcinogen in 2020, despite limited evidence on its effects on human health. To ensure that their now-black plastic products are immune to electrical fires, they also add in brominated flame retardants (BFRs) and organophosphate flame retardants (OPFRs) during production A 2024 Chemosphere study has also found that exposure to items containing high levels of BFRs and OPFRs can increase the risk of cancer, cause neurotoxicity and hormone disruption. Megan Liu, study co-author and science and policy manager at Toxic-Free Future, said: 'Companies continue to use toxic flame retardants in plastic electronics, and that's resulting in unexpected and unnecessary toxic exposures. 'These cancer-causing chemicals shouldn't be used to begin with, but with recycling, they are entering our environment and our homes in more ways than one. The high levels we found are concerning.' Experts believe that if your black plastic coffee maker is damaged or is consistently exposed to boiling water for long periods of time, the cancerous chemicals may start melting during the coffee-making process and slowly trickle down into your coffee cup. Once they enter the body, these chemicals act as endocrine disruptors, interfering with the body's hormonal system. This causes damage to cells and could lead to mutations that may become cancerous. While there is no risk with occasional or rare exposure to carbon black, BFRs and OPFRs, all three of these carcinogens can accumulate in the body and cause damage to vital organs such as the thyroid, breasts, lung and heart. A 2022 Environmental Pollution study found that long-term carbon black exposure might damage lung cell DNA, cause inflammation and pave the way for lung cancer development. A 2017 Duke University study also noted that due to excessive exposure to BFRs and OPFRs through kitchen products such as coffee machines, doctors are now finding these chemicals in the blood, breast milk and urine in nearly all of the Americans they tested. An April 2024 study that tracked over 1,000 Americans over two decades found people with high levels of flame retardants in their blood had a 300 percent higher risk of dying from cancer than people with low levels of the substances in their blood. They also found people were most susceptible to developing thyroid and breast cancer, which are known to be linked to endocrine disrupting chemicals. Similarly, research from Harvard School of Public Health found that 80 percent of women who were undergoing the fertility treatment in vitro fertilization to get pregnant had higher levels of flame retardants in their urine as compared to those who were not. Those with the highest levels of the chemicals in their body had a harder time getting pregnant, staying pregnant and giving birth to a live child than people with lower levels of the chemicals in their body. Apart from damage to American adults, the NIH also warns that flame retardants and their byproducts are especially harmful to children as their organs are still developing and they are more likely to be repeatedly exposed to them by placing plastic items in their mouth or playing with them. 'The health of women and children must be prioritized over the chemical industry profits. We need less poison plastic, more safer chemicals and materials, and an end to plastic ingredient secrecy,' Liu said. To avoid exposure, experts suggest opting for shorter, cooler brews that are BPA-free and made of stainless steel or glass parts. Furthermore, they suggest cleaning your machine and using filtered water to stop mineral and dirt build-up to limit exposure.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store